Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleEfficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy
Author(s)McCabe M, Smith FP, Goldberg D, Macdonald J, Woolley PV, Warren R
Journal, Volume, IssueInvestigational New Drugs 1988;6:243-246
Major outcome(s)THC decreased nausea and vomiting in 23 of 36 (64%) patients
IndicationNausea/vomiting;Cancer;Cancer chemotherapyAbstract
MedicationDelta-9-THC

Oral delta-9-tetrahydrocannabinol (THC), 15 mg/m2, was compared to prochlorperazine (PCZ), 10 mg. for the control of cancer chemotherapy-related emesis. Thirty-six patients whose vomiting was refractory to standard antiemetic therapy were entered in this randomized comparative cross-over study. THC decreased nausea and vomiting in 23 of 36 (64%) patients compared to 1 of 36 receiving PCZ. THC efficacy was not dependent on the class of antineoplastic-agent inducing the emetic symptoms, age of patients or type of sensorial change experienced. Using the 15 mg/m2 dose, all patients experienced transient sensorial changes, characterized as a pleasant "high" in 19 or a variable state of dysphoria in 17 cases. This study confirms the usefulness of THC in patients whose chemotherapy-induced nausea and vomiting is refractory to other standard antiemetics. While excellent antiemetic control was achieved at the dosage 15 mg/m2, dysphoria was encountered at this dose level and we recommend that an initial dose of 5 mg/m2 which, if necessary, can be carefully increased to achieve maximum antiemetic benefit.

Route(s)Oral
Dose(s)dronabinol 15 mg/m2 1 h before chemotherapy and every 4 h thereafter for 24 h
Duration (days)
Participants36 patients whose vomiting was refractory to standard antiem
DesignControlled study
Type of publication
Address of author(s)Division of Medical Oncology, Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, D.C. 20007
Full text

[Back to Overview]  [IACM Homepage]


up